Horizon Therapeutics to Acquire Viela Bio for ~ $3.05B

Share this


Horizon Therapeutics to Acquire Viela Bio for ~ $3.05B


  • Horizon to acquire Viela Bio for $53/ share- representing an equity value of $3.05B with a 53% premium over a closing price to Viela’s on Jan 29- 2020. Additionally- AstraZeneca to divest its 26.7% ownership in Viela Bio in an exchange of ~$760 - $780M
  • The transaction expected to close in Q1’21. The acquisition will bolster Horizon’s pipeline and expand its portfolio of rare diseases with the addition of Uplizna- VIB4920- VIB7734- VIB1116
  • Previously- Horizon has submitted a prior approval supplement to the US FDA to support increased scale production of Tepezza for TED

 ­ Ref: Businesswire | Image: CFO

Click here to­ read the full press release 

Senior Editor

This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com

Share this article on WhatsApp, LinkedIn and Twitter

Related News/Articles

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions